TRUMY (Terumo) ROCE %: 7.55% (As of Mar. 2026)


TRUMY Terumo Corp TRUMY
92 GF Score
Price $13.85
GF Value $19.40
Valuation Modestly Undervalued
View Full Analysis

What is Terumo ROCE %?

Terumo TRUMY +0.91% 92 ROCE % is 7.55% as of Mar. 2026. GuruFocus rates TRUMY with a GF Score™ of 92/100 and a GF Value™ of $19.40 (Modestly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Terumo's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.55%.

Terumo  (OTCPK:TRUMY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Terumo ROCE % Related Terms

Terumo ROCE % Historical Data

* Premium members only.

The historical data trend for Terumo's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Terumo ROCE % Chart

Terumo Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.25 8.45 9.56 10.61 10.49

Terumo Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.39 14.75 11.63 10.78 7.55
TRUMY
92GF Score
Terumo Corp TRUMY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Terumo ROCE % Calculation

Terumo's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=1144.031/( ( (12266.352 - 1616.59) + (14571.431 - 3407.624) )/ 2 )
=1144.031/( (10649.762+11163.807)/ 2 )
=1144.031/10906.7845
=10.49 %

Terumo's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=836.688/( ( (14475.432 - 3461.508) + (14571.431 - 3407.624) )/ 2 )
=836.688/( ( 11013.924 + 11163.807 )/ 2 )
=836.688/11088.8655
=7.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.55% mean?
Terumo (TRUMY) has a ROCE % of 7.55% as of Mar. 2026.
Is Terumo's ROCE % too high?
Terumo's current ROCE % is 7.55%. The Medical Devices & Instruments industry median ROCE % is 2.20. Terumo's value of 7.55% is 243.2% above this industry median. Overall, Terumo has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's ROCE % compare to ISRG and BDX?
Terumo's ROCE % of 7.55% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. Terumo's value of 7.55% is 243.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Terumo's current ROCE % of 7.55% is 243.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Terumo's current ROCE % is 7.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (TRUMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $19.40, compared to a current price of $13.85 — trading 28.6% below its estimated fair value. The current ROCE % is 7.55% and 243.2% above the Medical Devices & Instruments industry median of 2.20. Terumo's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Terumo (TRUMY), the current ROCE % is 7.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Terumo (TRUMY) Overvalued in 2026?

Based on GuruFocus' analysis, Terumo stock appears to be undervalued. The current stock price of $13.85 is trading 28.6% below its estimated GF Value™ of $19.40. GuruFocus considers Terumo to be Modestly Undervalued.

Key valuation signals for TRUMY:

  • ROCE %: 7.55%
  • GF Value™: $19.40 vs. price of $13.85 (28.6% below fair value)
  • GF Score™: 92/100
  • Industry Position: 243.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the TRUMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Terumo Business Description

Address 2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
92GF Score

Get the complete analysis for TRUMY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.85
Price
$19.40
GF Value